source
- Karyopharm Secures One-Month Debt Extension While Awaiting Xpovio DecisionKaryopharm Therapeutics, facing cash constraints, has negotiated a temporary reprieve on a $15.8 million debt that was due. Under the agreement, lenders and noteholders will refrain from enforceme…
- mRNA cancer vaccines’ biggest barriers to marketManufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.